Table 3 Bivariate analysis of variables collected on D1 influencing the outcome, at ICU discharge, of pneumococcal CAP*
From: Severe pneumococcal pneumonia: impact of new quinolones on prognosis
Variables | Survivors n = 44 | Non survivors n = 26 | p |
|---|---|---|---|
Age > 70 yrs. | 14 (31.8%) | 16 (61.6%) | 0.01 |
Gender: Male/Female | 33/11 | 20/6 | 0.85 |
Malignancy | 4 (9.0%) | 1 (3.8%) | 0.41 |
Diabetes mellitus | 7 (15.5%) | 4 (15.4%) | 0.95 |
Chronic heart failure | 4 (9.1%) | 7 (26.9%) | 0.04 |
Chronic respiratory insufficiency | 8 (18.2%) | 4 (15.4%) | 0.76 |
Immunosuppression | 10 (22.7%) | 3 (11.5%) | 0.24 |
SAPS II >50 | 18 (40.1%) | 19 (73.1%) | 0.009 |
LOD >8 | 13 (29.5%) | 16 (61.6%) | 0.008 |
SOFA >8 | 14 (31.8%) | 18 (69.3%) | 0.002 |
PSI 4/5 | 17/27 | 4/22 | 0.04 |
MV on D1 | 32 (72.7%) | 23 (88.4%) | 0.12 |
Septic shock | 14 (31.8%) | 20 (76.9%) | 0.0003 |
Bacteremia | 14 (31.8%) | 11 (42.3%) | 0.37 |
Patients in Group A/Group B | 21/23 | 17/9 | 0.15 |
Cephalosporin in initial treatment | 30 (68.2%) | 16 (61.6%) | 0.57 |